Sure, sure. So let me start with the Precision Devices, first. I think, as we look at it, I would say, the exposure to that life sciences market is between $25 million and $30 million in 2019. We expect that to be down, I would say probably about 15% to 20% for the full year. But it's really, as we see it today, highly in Q2 and Q3. We started seeing weakness in Q2. It was, obviously, later than what happened within the Hearing Health market. And that is definitely a weakness. But I mean, again, these are things like pacemakers, other implantable as well as installation of new MRI machines. And so, we expect this is going to come back. It's just a matter of when. I think, it's kind of in the same vein as we talk about the Hearing Health market, it will come back. As far as Hearing Health, as John mentioned, I mentioned, sales in Q2 were down close to 50%, from prior year levels. But we did see a fair amount of improvement through the quarter that it got a lot better as we got later in the quarter. I mean, right now -- my best estimate right now is probably the Hearing Health market will probably be down, maybe a little over 20%, maybe year-over-year or so. And so I think, we’re getting increasingly confident that we're starting to see that recovery. Our customers are getting more bullish about the recovery. Obviously, I have to practice this all with -- that if there's something that changes significantly with COVID again, that could all change. But right now, we're feeling good that when I said, last year, it could be to the -- even maybe the second quarter of next year to return to normal levels. Right now, I'd probably say that's pushing a little bit inward as opposed to staying the same or pushing out.